WuXi Biologics Reports Solid 2024 Interim Results
- Written by PR Newswire
Revenue increased by 1.0% YoY to RMB 8,574.2 millionNon-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%Added 61 new integrated projects, including 4 from late-phase and commercial stageClient's molecule recently acquired by MNC, highlighting a potential best-in-class CD3 asset...
Read more: WuXi Biologics Reports Solid 2024 Interim Results














